Treatment of ANCA-associated vasculitis, where to go?

@article{Kallenberg2012TreatmentOA,
  title={Treatment of ANCA-associated vasculitis, where to go?},
  author={CeesG. M. Kallenberg},
  journal={Clinical reviews in allergy & immunology},
  year={2012},
  volume={43 3},
  pages={
          242-8
        }
}
The introduction of (oral) cyclophosphamide (CYC) in the treatment of ANCA-associated vasculitides (AAV) has strongly improved prognosis but the side effects of long-term CYC treatment are serious. A number of recent randomized controlled studies have shown that the cumulative dose of CYC can be strongly reduced in the treatment of AAV or even reduced to zero. Maintenance treatment can be performed with azathioprine (AZA), or methotrexate (MTX) in case of intolerance, although the intensity and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Long-term efficacy and safety results of the RAVE trial

  • U Specks, JH Stone
  • RAVE-ITN Research Group
  • 2011
2 Excerpts